Clinical Trials
14 trialsNCT07274774 2026-04-28
SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT07179900 2025-12-11
Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma
Hebei Medical University Fourth Hospital
Phase 2 Not yet recruiting
NCT06994299 2025-11-18
PRISM
Weill Medical College of Cornell University
Phase 2 Withdrawn
NCT04791176 2025-08-14
Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed
NCT06870942 2025-03-11
Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy
Shanghai Zhongshan Hospital
Phase 2 Recruiting
NCT02182687 2024-03-05
SBRTvsTACE
Lahey Clinic
Phase 2 Completed
NCT05010434 2023-09-21
Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT04653389 2022-01-11
Perioperative Therapy for Hepatocellular Carcinoma
Zhejiang University
Phase 2 Terminated
NCT04193696 2020-01-09
RT+ Anti-PD-1 for Patients With Advanced HCC (RT+PD-1-HCC)
Guangxi Medical University
Phase 2 Unknown
NCT03520257 2018-05-09
The Study of Apatinib Plus Radiotherapy vs. Apatinib in the Treatment of Hepatocellular Carcinoma With BCLC-C Stage I and Stage II Portal Vein Tumor Thrombus
Guangxi Medical University
Phase 2 Unknown
NCT01432314 2014-06-26
RTANDTACE
Asan Medical Center
Phase 2 Withdrawn
NCT00002608 2013-07-10
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00030511 2012-07-16
Radiation Therapy and Fluorouracil Before Surgery in Treating Patients With Primary or Recurrent Bile Duct Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT00154817 2005-11-22
A Phase II Study of Radiotherapy for Locally Advanced Hepatocellular Carcinoma (HCC)
National Taiwan University Hospital
Phase 2 Completed